Key Points
- CFO Howard Horn sold 3,061 shares on Feb. 2 at an average price of $23.56 for $72,117.16, trimming his stake by 3.33% to 88,935 shares (also sold 3,081 shares in December), signaling notable insider selling activity.
- Ultragenyx is trading around $24.80 with a $2.39B market cap but recently reported a large EPS miss (‑$1.81 vs. ‑$1.23 expected), negative margins and ROE; analysts collectively rate the stock a "Moderate Buy" with a consensus price target of $72.29 despite several downward revisions.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 3,061 shares of the company's stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $23.56, for a total transaction of $72,117.16. Following the completion of the transaction, the chief financial officer owned 88,935 shares in the company, valued at approximately $2,095,308.60. This represents a 3.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Howard Horn also recently made the following trade(s):
- On Wednesday, December 10th, Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $36.38, for a total transaction of $112,086.78.
Ultragenyx Pharmaceutical Trading Up 0.2%
NASDAQ RARE opened at $24.80 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.41 and a 1-year high of $46.50. The firm's fifty day simple moving average is $28.70 and its 200-day simple moving average is $29.97. The company has a market capitalization of $2.39 billion, a PE ratio of -4.18 and a beta of 0.16.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.58). The firm had revenue of $159.93 million during the quarter, compared to analysts' expectations of $167.42 million. Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The business's revenue for the quarter was up 14.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.40) EPS. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.
Analysts Set New Price Targets
RARE has been the topic of several analyst reports. Weiss Ratings restated a "sell (e+)" rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Guggenheim cut their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a "buy" rating on the stock in a report on Monday, January 5th. Wells Fargo & Company reduced their price target on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an "overweight" rating for the company in a research report on Tuesday, December 30th. Barclays decreased their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, November 24th. Finally, Robert W. Baird decreased their target price on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an "outperform" rating for the company in a research report on Tuesday, December 30th. Sixteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus price target of $72.29.
Read Our Latest Research Report on Ultragenyx Pharmaceutical
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Assetmark Inc. increased its holdings in Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 1,024 shares during the period. Huntington National Bank boosted its position in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 393 shares in the last quarter. Danske Bank A S bought a new stake in Ultragenyx Pharmaceutical in the third quarter valued at about $39,000. Smartleaf Asset Management LLC raised its position in Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 1,169 shares in the last quarter. Finally, Covestor Ltd raised its position in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 369 shares in the last quarter. 97.67% of the stock is owned by institutional investors.
Ultragenyx Pharmaceutical Company Profile
(
Get Free Report)
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
